C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

C4 Therapeutics, Inc.

C4 Therapeutics is involved in the development of targeted protein degradation therapies for treating diseases, self-described as a new generation of medicine.

Metric
Company Name	C4 Therapeutics, Inc.
Symbol	CCCC
MSH ID	COM:C4THERAPEUTICS
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	145
Website	c4therapeutics.com
LinkedIn
Founders

Metric
Market Cap	344.03M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	20.76M
Revenue (LTM)
Revenue (NTM)
Gross Profit	13.02M
EBITDA	-131.29M
Operating Income	-139.03M
Net Income	-132.49M
EPS	-2.67
Diluted EPS	-2.67
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.74
Operating Profit Margin	-4.05
EBITDA Margin	-6.33
Net Profit Margin	-3.67
Return on Equity	-0.45
Return on Assets	-0.28
Return on Capital Employed	-0.36

COM:C4THERAPEUTICS

C4 Therapeutics

Last Close

4.01

22/11 21:00

Market Cap

344.03M

Beta: -

Volume Today

1.36M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-1.97
P/B Ratio	1.21
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	27.92
EV Multiple	-2.46

Metric
Days Sales Outstanding	8.97
Days Payables Outstanding
Days Inventory Outstanding	0.00
Operating Cycle	292.03
Cash Conversion Cycle	187.19
Asset Turnover	0.08

Metric
Operating Cash Flow	-106.84M
Free Cash Flow	-108.55M
Cash Flow to Debt	-1.14
Operating Cash Flow/Sales	-2.65
Free Cash Flow Yield	-0.44

Metric
Cash & Equivalents	126.59M
Accounts Receivable	-10.33M
Inventory
Goodwill
Debt to Capitalization	0.22
Debt to Assets	0.22
Current Ratio	7.39
Quick Ratio	6.21

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	1.37
R&D to Revenue	5.80
SG&A to Revenue	2.08